Corvus Pharmaceuticals/$CRVS

Corvus Pharmaceuticals shares are trading higher after announcing full data from Cohort 3 of its Phase 1 trial of soquelitinib for atopic dermatitis, showing earlier and deeper responses.
2 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Corvus Pharmaceuticals

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Ticker

$CRVS
Trading on

Industry

Biotechnology

Employees

31

ISIN

US2210151005

CRVS Metrics

BasicAdvanced
$302M
-
-$0.99
0.66
-

What the Analysts think about CRVS

Analyst ratings (Buy, Hold, Sell) for Corvus Pharmaceuticals stock.

CRVS Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

CRVS Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CRVS

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs